{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-095741","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.277613+00:00","generated_at":"2026-06-07T12:46:27.970561+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeuroOne Q4 product revenue $742K vs $69K YoY; net loss $3.1M; FDA clears OneRF Ablation System","bullets":["Product revenue $742K (Q4) vs $69K YoY; full year $1.952M vs $171K.","Net loss $3.1M (Q4) vs $1.4M; full year $11.9M vs $10.0M.","Received FDA 510(k) clearance for OneRF Ablation System in Dec 2023; commercial launch expected H1 2024.","Cash $5.3M as of Sep 30, 2023, down from $11.1M; raised $5.2M net in public offering and $2.5M via ATM at $1.77/share.","Zimmer Biomet expanding Evo sEEG launch; device sales ramp expected quarter by quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-095741","json":"https://secwatch.observer/filing/0001213900-23-095741.json","markdown":"https://secwatch.observer/filing/0001213900-23-095741.md","text":"https://secwatch.observer/filing/0001213900-23-095741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023095741/0001213900-23-095741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023095741/ea189916-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:46:27.970561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"285d45731dab6b9cac53d715578bff6b40fa6405","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal fourth quarter and full fiscal year ended September 30, 2023 results: revenue Product revenue of $742,000 in Q4 2023, net income Net loss was $3.1 million for the fourth quarter of fiscal 2023.","evidence_excerpt":"On December 14, 2023, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter and fiscal year ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023095741/0001213900-23-095741-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal fourth quarter and full fiscal year ended September 30, 2023"},{"label":"Revenue","value":"Product revenue of $742,000 in Q4 2023"},{"label":"Net income","value":"Net loss was $3.1 million for the fourth quarter of fiscal 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"98921cc8f087f89801db2c4f339588f5f4880c80","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp reported full fiscal year ended September 30, 2023 results: revenue Product revenue of $1,952,000 for FY 2023, net income Net loss was $11.9 million for the full year fiscal 2023.","evidence_excerpt":"today announces its operating results for the fiscal fourth quarter and full fiscal year ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023095741/0001213900-23-095741-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full fiscal year ended September 30, 2023"},{"label":"Revenue","value":"Product revenue of $1,952,000 for FY 2023"},{"label":"Net income","value":"Net loss was $11.9 million for the full year fiscal 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}